Genomic Determinants of Outcome in Cardiogenic Shock
ConditionCardiogenic Shock
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorBarts & The London NHS Trust
About this trial
The aim of this project is to understand the heterogeneity of both the immune consequences and treatment responses in CS. We will explore this heterogeneity through identification of transcriptomic sub-phenotypes and their association with outcomes, including therapeutic responses.
Eligibility criteria
Qualifiers
Willing to provide informed consent or appropriate consent from a nominated consultee or personal consultee
Presentation within 24 hours of onset of ACS symptoms.
CS can only be secondary to ACS (Type 1 MI STEMI or N-STEMI) or myocarditis
Planned or completed revascularisation of culprit coronary artery
Disqualifiers
Unwilling to provide informed consent.
Echocardiographic evidence (recorded within 90 mins of end of PCI procedure) of mechanical cause for CS: eg ventricular septal defect, LV-free wall rupture, ischaemic mitral regurgitation.
Age <18 and ≥80 years.
Shock from another cause (sepsis, haemorrhagic/hypovolaemic shock, anaphylaxis, etc).
Trial design
Treatments tested in this trial
- Observational study
Treatment groups
300 Participants
are divided into 5 treatment groupsSponsors and collaborators
Barts & The London NHS Trust
Lead sponsor
University of Oxford
Collaborator
Source ClinicalTrials.gov